Giuseppina Astone
A5000970720- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- Lymphoma Diagnosis and Treatment
- Prostate Cancer Treatment and Research
- Biosimilars and Bioanalytical Methods
- T-cell and Retrovirus Studies
- Silk-based biomaterials and applications
- Chronic Lymphocytic Leukemia Research
- Acute Lymphoblastic Leukemia research
- Immune Cell Function and Interaction
- Antimicrobial Peptides and Activities
New York Hospital Queens
2025
Presbyterian Hospital
2025
NewYork–Presbyterian Hospital
2025
Cornell University
2021-2025
University of Genoa
2021-2023
Weill Cornell Medicine
2021-2023
Peripheral T cell lymphomas (PTCLs) comprise heterogeneous malignancies with limited therapeutic options. To uncover targetable vulnerabilities, we generate a collection of PTCL patient-derived tumor xenografts (PDXs) retaining histomorphology and molecular donor-tumor features over serial xenografting. PDX demonstrates remarkable heterogeneity, complex intratumor architecture, stepwise trajectories mimicking primary evolutions. Combining functional transcriptional stratification...
Abstract Debate is around the optimal immunization regimen for cancer vaccines since too intense vaccination schedules may exhaust reactive lymphocytes. GX301 a telomerase-based vaccine whose safety and immunological effects were tested in phase I trial applying an eight administrations schedule. Main objective of this study was to comparatively analyse response three regimens metastatic castration-resistant prostate patients with response/disease stability after docetaxel chemotherapy. This...
Head and neck squamous cell carcinoma (HNSCC) has a poor clinical outcome despite the presence of rich CD8+ T tumor infiltrate in majority patients. This may be due to alterations infiltrating cells. Here, we performed characterization HNSCC cells cohort 30 The results showed that differential intratumoral frequency CD8+CD28+ cells, CD8+CD28− CD8+CD28−CD127−CD39+ Treg distinguished between patients who did or not respond treatment. Moreover, high PD1 expression identified subpopulation,...
Background The current challenge for immunotherapies is to generate effective antitumor immunity. Since tumor immune escape mechanisms do not impact pre-existing and consolidated responses, we tested the hypothesis of redirecting a pregenerated immunity cancer: recall non-tumor antigen response against tumor, silk fibroin nanoparticles (SFNs) have been selected as ‘Trojan-horse’ carriers, promoting uptake by cells. Methods SFNs loaded with either ovalbumin (OVA) or CpG oligonucleotide (CpG)...
T-cell lymphomas (TCLs) comprise a heterogeneous group of malignancies. Current therapeutic options remain limited, partly given the scarcity representative preclinical models. To uncover targetable vulnerabilities, we created collection TCL patient-derived-tumor-xenografts (PDXs) retaining molecular and histomorphology donor tumor features over serial xeno-grafting while capturing their mechanisms lymphomagenesis evolution. Ex-vivo cultures in-vivo experiments demonstrated remarkable...